Allogene Therapeutics ALLO Interest Expense
Interest Expense at other companies
Other financials
Where this comes from
Reported directly by Allogene Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:InterestExpenseNonoperating.
The official record: Allogene Therapeutics’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Allogene Therapeutics's interest expense.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Allogene Therapeutics's interest expense?
- Allogene Therapeutics (ALLO) reported interest expense of $300K in Q1 2026.
- How has Allogene Therapeutics's interest expense changed year-over-year?
- Allogene Therapeutics's interest expense increased by 100.0% year-over-year, from $150K to $300K.
- What does interest expense mean?
- Cost of borrowing — interest paid or accrued on bonds, bank loans, credit facilities, finance leases, and other debt obligations.